[PDF][PDF] Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical …

MG Kris, LE Gaspar, JE Chaft, EB Kennedy… - J Clin …, 2017 - cancercareontario.ca
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely
Resected Non–Small-Cell Lung Cancers: Page 1 JOURNAL OF CLINICAL ONCOLOGY …

[HTML][HTML] Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions

Y Wang, W Deng, N Li, A Sharma, W Jiang… - Frontiers in …, 2018 - frontiersin.org
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the
development of anticancer immunotherapy agents has thrived. The success of many …

A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors

BP Venkatesulu, S Mallick, SH Lin… - Critical reviews in oncology …, 2018 - Elsevier
Lymphopenia is a common accompaniment of multimodal cancer therapy. As the most
radiosensitive cells of the hematopoietic system, lymphocytes residing within or circulating …

Integrating genomic features for non-invasive early lung cancer detection

JJ Chabon, EG Hamilton, DM Kurtz, MS Esfahani… - Nature, 2020 - nature.com
Radiologic screening of high-risk adults reduces lung-cancer-related mortality,; however, a
small minority of eligible individuals undergo such screening in the United States,. The …

The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression

G Lei, Y Zhang, P Koppula, X Liu, J Zhang, SH Lin… - Cell research, 2020 - nature.com
Ferroptosis, a form of regulated cell death caused by lipid peroxidation, was recently
identified as a natural tumor suppression mechanism. Here, we show that ionizing radiation …

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

WSME Theelen, D Chen, V Verma… - The Lancet …, 2021 - thelancet.com
Background Radiotherapy might augment systemic antitumoral responses to
immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with …

[HTML][HTML] Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects

YL Xu, RK Reinscheid, S Huitron-Resendiz, SD Clark… - Neuron, 2004 - cell.com
Arousal and anxiety are behavioral responses that involve complex neurocircuitries and
multiple neurochemical components. Here, we report that a neuropeptide, neuropeptide S …

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified …

JY Chang, RJ Mehran, L Feng, V Verma, Z Liao… - The Lancet …, 2021 - thelancet.com
Background A previous pooled analysis of the STARS and ROSEL trials showed higher
survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early …

Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer

SH Lin, L Wang, B Myles, PF Thall, WL Hofstetter… - International Journal of …, 2012 - Elsevier
PURPOSE: Although 3-dimensional conformal radiotherapy (3D-CRT) is the worldwide
standard for the treatment of esophageal cancer, intensity modulated radiotherapy (IMRT) …

[HTML][HTML] Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

J Welsh, H Menon, D Chen, V Verma… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background In this phase I/II trial, we evaluated the safety and effectiveness of
pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from …